New migraine drug being considered by European Commission after ‘good results’
By Mark Keane
A new drug to prevent migraines could soon become accessible to Irish sufferers.
Emgality, a preventative drug, has received marketing authorisation by the European Medicines Agency, which has resulted in it now being considered by the European Commission.
It’s estimated that half a million people in Ireland suffer from migraines, suffering from symptoms such as nausea, vomiting, an increased sensitivity to light or sound, as well as affecting a person’s ability to function physically.
According to Brian Hayes MEP, Emgality would be administered via injection to patients who suffer from at least four migraine days per month.
Three trials involving 1,780 patients yielded “good results”, according to Mr Hayes – and for patients with chronic migraine, the reduction was 2 days.
“As sufferers will know, there is no cure for migraine,” Mr Hayes said.
“Existing preventative treatments don’t always work well and some have unpleasant side effects.
“The European Commission is expected to decide on whether this drug should be distributed within the next two months and Department of Health officials need to keep a close eye on this.
He added that he will call on the Government to “fast-track” the circulation of Emgality to ensure those who “need it most, get it”.
TAGS news
